Speaker illustration

Doctor Carlos Alberto Paterno Marchioli

Cardiovascular Research., Castiglion Fiorentino (Italy)

Member of:

European Society of Cardiology

I graduated in 1969 from the University of Buenos Aires. Director of the Council of Epidemiology and Cardiovascular Prevention of the Argentine Society of Cardiology. President of the Cardiology Society of Buenos Aires of the Argentine Federation of Cardiology. Advisor to the Ministry of Health of the Argentine Republic. Since 2003 he has started to work in Italy. Since 2007 founding a Cardiovascular Research Center and non-invasive applanation tonometry was used. Eighty-one studies were carried out, the most important: First national epidemiological study on coronary risk factors in Sud America (FRICAS study - Argentine). Prize of the National Academy of Medicine of Buenos Aires - 1996. First national epidemiological study on risk factors in adolescence (FRICELA study - Argentine). First epidemiological study on the association of coronary risk factors in old age (AFRICA study - Argentine). I'm working to prevent AF/ventricular extrasystoles without use of antiarrhythmic.

Is the minimal mitral regurgitation a marker of high blood pressure, and can predispose to the appearance of atrial fibrillation?

Event: ESC Congress 2021 - The Digital Experience

Topic: Prevention

Session: Hypertension e-posters

Thumbnail

Angiotensin receptor blockers and mineralocorticoid receptor antagonists therapy reaches better central haemodynamic parameters and avoid the episodes of atrial fibrillation

Event: ESC Congress 2020

Topic: Pharmacotherapy

Session: Hypertension ePosters

Thumbnail

Assess of angiotensin receptor blockers therapy associated to mineralocorticoid receptor antagonists or to calcium channel blockers plus hydrochlorothiazide according central haemodynamic parameters

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Hypertension treatment: drugs and devices

Thumbnail

Improvement in central haemodynamic parameters by association of angiotensin II receptors blockers and canrenone therapy in obese hypertensive patients

Event: HEART FAILURE 2016

Topic: Renin-angiotensin-aldosterone antagonists

Session: Renin-angiotensin-aldosterone antagonists

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb